Press Releases Details

Full unedited text from Ashesh’s Interview with The Global Message at BIO 2024

Oulu, Finland 27th June 2024:

My name is Dr. Ashesh Kumar and I am the CEO and Director of Biologics, Paras Biopharma Finland.

Paras Biopharma is a Finland-based company.  We are a company which is serving on the Biologics CDMO side and also we have some of the biologics as the biosimilar drugs that we are developing.  In Finland we have a very ‘state-of-the-art’ biologics infrastructure for scale-up production of the biologics in Finland and that enables us to develop some of these products in a very efficient manner.

Paras Biopharma has developed some of the very efficient technologies for production of biologics; this enables actually a very low-cost production some of the challenging proteins or the challenging medicinal products and this, I think, is one of the key enablers within the industry.

Paras Biopharma is doing some of the very complex proteins and making a very efficient production.  One of the technologies that we have is called Diabrid NobleCleav Technology and this technology enables very high titers of biologics within some of the microbial systems and that leads to a very efficient production of these biologics.

We had almost 10 years back, we had developed a technology called Cytofold StructQuant Technology.  This technology enables the soluble active protein within the cytoplasma of the microbial host strains, especially E. coli, and when we were able to achieve this, this was an amazing moment or rather an amazing time for us which we successfully implemented for production of some of the complex proteins.  So, this is where we started developing some of the products like Interleukin Receptor Antagonist; we went into also other complex proteins actually for the development of scale-up production of these biologics.

A company like Paras, we are....you know in Finland, ‘Paras’ is known as ‘best’, so we have created some of the best ways of producing some of these biologics and even if a company is large, they may not have the exact know-how or the detail in what we go into as a small company, and we serve small, medium and large biopharma companies around the globe.

So, Paras Biopharma focuses to produce Biologics in Microbial Hosts, which is a very specialised host – it needs specialised knowledge and in this sector, we have developed very substantial knowledge to produce the biologics very efficiently and economically and this is, I think, our key determinant and key differentiator within the industry.

We are Paras Biopharma, serving in companies in US and Europe, both.  We have customers in the West-Coast area and also customers in the East Coast in Boston area.  We are serving some of the challenging therapy companies within Europe.  We are producing one of the largest and challenging therapy Enzymes, so we have several customers who we are serving within Europe and US, bringing these differentiators, to them.

So Paras Biopharma is now with its infrastructure, we are expanding our facility.  Currently we are on Microbial Space, 150 L and 750 L bioreactors.  We have of course matching Downstream and very state-of-art Analytical and Quality Labs.  We are planning to expand our facility, and this is what we will bring to our customers, going forward. 

Our key strengths are our technologies, our technology platform that we have.  And I am also happy to share that we definitely very well serving our biopharma customers in Europe and US...and our Biosimilar pipeline, especially the product for Blood Platelet Disorder, which is Immune Thrombocytopenia Purpura – I think this ITP product is very well progressing and we believe that we can bring through our internal pipeline also, some of the best products for customers and patients going forward.